摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

cis-2-Ethyl-pent-2-en-saeure | 19052-05-2

中文名称
——
中文别名
——
英文名称
cis-2-Ethyl-pent-2-en-saeure
英文别名
2-Ethyl-pent-2c-ensaeure;(Z)-2-ethyl-pent-2-enoic acid;(Z)-2-ethylpent-2-enoic acid
cis-2-Ethyl-pent-2-en-saeure化学式
CAS
19052-05-2
化学式
C7H12O2
mdl
——
分子量
128.171
InChiKey
NEYTTWNDEATJBU-WAYWQWQTSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    9
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds
    申请人:——
    公开号:US20030060624A1
    公开(公告)日:2003-03-27
    The present invention relates to processes for the preparation of any of the intermediate 1,3-substituted indenes of the formulae (Ia), (Ib) and (Ic) or a mixture thereof: 1 wherein R 1 , R 2 , R 3 , R 4 , and R 5 are defined herein. Compounds of formulae (Ia), (Ib) and (IC) or mixtures thereof are useful in the preparation of compounds of formula (II): 2 wherein R 2 , R 3 and R 6 are also defined herein.
    本发明涉及制备公式(Ia)、(Ib)和(Ic)中任一中间体1,3-取代吲哚的过程,或其混合物: 其中R1、R2、R3、R4和R5在此处定义。公式(Ia)、(Ib)和(Ic)或其混合物的化合物在制备公式(II)的化合物中有用: 其中R2、R3和R6也在此处定义。
  • Heterocyclic sulfonamide inhibitors of beta amyloid production
    申请人:ArQule
    公开号:US20020183361A1
    公开(公告)日:2002-12-05
    Compounds of Formula (I), 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof. Methods of using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are described
    提供了符合以下定义的化合物(I)的化合物,其中R1、R2、R3、R4、R5、R6、T、W、X、Y和Z的定义如下,以及其药用盐、水合物和/或前药。描述了使用这些化合物抑制β淀粉样蛋白产生以及治疗阿尔茨海默病和唐氏综合征的方法。
  • Method for producing anellated tetrahydro-{1h}-triazoles
    申请人:——
    公开号:US20040097728A1
    公开(公告)日:2004-05-20
    The present invention relates to a process for preparing fused tetrahydro-[ 1 H]-triazoles of the formula I 1 where the variables R a , Z, Z 1 , X, W, n and Q are as defined in claim 1, by cyclization of compounds of the formula II 2 where R is C(X)OR 2 or C(X)SR 2 , where X is oxygen or sulfur, and R 2 is as defined in claim 1, in the presence of a base. The invention also relates to compounds of the formula I where W is sulfur if Z is a methylene group optionally substituted by R a , and furthermore to compounds of the formula I where Q is a benzoxazole or benzothiazole radical, and to the use of these compounds as herbicides.
    本发明涉及一种制备公式I的熔融四氢咪唑的方法,其中变量Ra、Z、Z1、X、W、n和Q如权利要求1中定义,通过在碱存在下,将公式II的化合物环化得到,其中R为C(X)OR2或C(X)SR2,其中X为氧或硫,R2如权利要求1中定义。该发明还涉及公式I的化合物,其中如果Z是可选地由Ra取代的亚甲基基团,则W为硫,此外还涉及公式I的化合物,其中Q为苯并噁唑或苯并噻唑基团,并将这些化合物用作除草剂。
  • [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
    申请人:REVIRAL LTD
    公开号:WO2021032992A1
    公开(公告)日:2021-02-25
    Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; either (i) T is N, Z is C, ---a--- and --­c--- are bonds, and ---b--- and ---d--- are absent; or (ii) T is C, Z is N, ---b--- and ---d--- are bonds, and ---a--- and ---c--- are absent; each of R3 and R4 is independently halo, -OR6, -NR6R7, -COR8, -C(O)OR8, -CON(R8)2 or -R6; R5 is H or halo; each of R6 and R7 is independently H or a group selected from C1-C6 alkyl, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, the group being unsubstituted or substituted; R8 is H or C1-C6 alkyl, each R8 being the same or different when two are present; n is 0 or 1; and one of V, W, X and Y is N or CH and the other three are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.
    公式(I)的苯二氮卓类衍生物:(I)其中:R1和R2中的每一个独立地是H或卤素;要么(i)T是N,Z是C,---a---和--c---是键,---b---和---d---是不存在的;要么(ii)T是C,Z是N,---b---和---d---是键,---a---和---c---是不存在的;R3和R4中的每一个独立地是卤素,-OR6,-NR6R7,-COR8,-C(O)OR8,-CON(R8)2或-R6;R5是H或卤素;R6和R7中的每一个独立地是H或从C1-C6烷基,C3-C10环烷基,C6-C10芳基,4-至10成员杂环烷基和4-至10成员杂芳基中选择的基团,该基团未取代或取代;R8是H或C1-C6烷基,当两个存在时R8相同或不同;n为0或1;V、W、X和Y中的一个是N或CH,另外三个是CH;其药用可接受的盐为RSV的抑制剂,因此可用于治疗或预防RSV感染。
  • [EN] ALTERNATE PROCESSES FOR THE PREPARATION OF PYRROLIDINE DERIVATIVES<br/>[FR] PROCÉDÉS ALTERNATIFS POUR LA PRÉPARATION DE DÉRIVÉS DE PYRROLIDINE
    申请人:DR REDDYS LABORATORIES LTD
    公开号:WO2019016745A1
    公开(公告)日:2019-01-24
    Aspects of the present application relate to process for the preparation of Pyrrolidine derivatives useful as key intermediates for active ingredients. Specific aspects relate to alternate process for the preparation of Upadacitinib intermediate, 4-ethylpyrrolidine-3-carboxylic acid, its ester or a salt thereof. Processes disclosed here in are cost effective and industrially viable as compared to known processes.
    本申请涉及一种用于制备吡咯烷衍生物的过程,该衍生物可用作活性成分的关键中间体。具体方面涉及一种用于制备Upadacitinib中间体4-乙基吡咯烷-3-羧酸、其酯或其盐的替代过程。与已知过程相比,本文披露的过程具有成本效益且在工业上可行。
查看更多